Advertisement

Infections in Allogeneic Stem Cell Transplantation

  • Marcus R. PereiraEmail author
  • Stephanie M. Pouch
  • Brian Scully
Chapter

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a widely used modality of therapy for a variety of malignant and nonmalignant diseases. Despite advances in pharmacotherapy and transplantation techniques, infection remains one of the most severe and frequently encountered complications of allo-HSCT.

This chapter will address the risk factors for development of infection following allo-HSCT, including those related to the host, the conditioning regimen, and the graft, as well as the timing of opportunistic infections after allo-HSCT. The most common bacterial, viral, fungal, and parasitic infections, as well as issues surrounding their diagnostics and treatment, will be discussed. Finally, this chapter will address vaccination and other preventative strategies to be utilized when caring for patients undergoing allo-HSCT.

Keywords

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) Opportunistic infection Bacterial, viral, fungal, and parasitic infections Vaccination Preventative strategies 

References

  1. 1.
    Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Wingard JR, Leather HL. Empiric antifungal therapy for the neutropenic patient. Oncology (Williston Park). 2001;15(3):351–63. discussion 363–4, 367–9Google Scholar
  3. 3.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Lortholary O, Gangneux JP, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, et al. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007). Clin Microbiol Infect. 2011;17(12):1882–9.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Kontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303–6.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5–14.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Hersh EM, Carbone PP, Wong VG, Freireich EJ. Inhibition of the primary immune response in man by anti-metabolites. Cancer Res. 1965;25(7):997–1001.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Filipovich A. Hematopoietic cell transplantation for correction of primary immunodeficiencies. Bone Marrow Transplant. 2008;42(Suppl 1):S49–52.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Smith AR, Gross TG, Baker KS. Transplant outcomes for primary immunodeficiency disease. Semin Hematol. 2010;47(1):79–85.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Scott BL, Park JY, Deeg HJ, Marr KA, Boeckh M, Chauncey TR, et al. Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2008;14(7):799–806.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Verschraegen CF, van Besien KW, Dignani C, Hester JP, Andersson BS, Anaissie E. Invasive Aspergillus sinusitis during bone marrow transplantation. Scand J Infect Dis. 1997;29(4):436–8.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8(9):512–20.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Nucci M, Andrade F, Vigorito A, Trabasso P, Aranha JF, Maiolino A, De Souza CA. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transpl Infect Dis. 2003;5(4):167–73.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Eyrich M, Lang P, Lal S, Bader P, Handgretinger R, Klingebiel T, et al. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors. Br J Haematol. 2001;114(2):422–32.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Safdar A, Rodriguez GH, De Lima MJ, Petropoulos D, Chemaly RF, Worth LL, et al. Infections in 100 cord blood transplantations: spectrum of early and late posttransplant infections in adult and pediatric patients 1996–2005. Medicine (Baltimore). 2007;86(6):324–33.CrossRefGoogle Scholar
  16. 16.
    van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(12):1487–98.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110(2):490–500.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Demopoulos L, Polinsky M, Steele G, Mines D, Blum M, Caulfield M, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc. 2008;40(5):1407–10.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin N Am. 2010;24(2):257–72.CrossRefGoogle Scholar
  20. 20.
    Bjorklund A, Aschan J, Labopin M, Remberger M, Ringden O, Winiarski J, Ljungman P. Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;40(11):1055–62.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Yamasaki S, Heike Y, Mori S, Fukuda T, Maruyama D, Kato R, et al. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens. Transpl Infect Dis. 2008;10(4):252–9.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012;49(1):10–4.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000;49(RR-10):1–125, CE1–7.Google Scholar
  24. 24.
    Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33(2):139–44.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Marena C, Zecca M, Carenini ML, Bruschi A, Bassi ML, Olivieri P, et al. Incidence of, and risk factors for, nosocomial infections among hematopoietic stem cell transplantation recipients, with impact on procedure-related mortality. Infect Control Hosp Epidemiol. 2001;22(8):510–7.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Gluckman E, Lotsberg J, Devergie A, Zhao XM, Melo R, Gomez-Morales M, et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet. 1983;2(8352):706–8.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;100(6):823–8.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325(18):1274–7.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Persons DA, Laughlin M, Tanner D, Perfect J, Gockerman JP, Hathorn JW. Fluconazole and Candida krusei fungemia. N Engl J Med. 1991;325(18):1315.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37(9):1847–9.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, Bartelt LA, Kilborn SB, Hoth PL, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004;39(4):584–7.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191(8):1350–60.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Lionakis MS, Kontoyiannis DP. Sinus zygomycosis in a patient receiving voriconazole prophylaxis. Br J Haematol. 2005;129(1):2.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    van Well GT, van Groeningen I, Debets-Ossenkopp YJ, van Furth AM, Zwaan CM. Zygomycete infection following voriconazole prophylaxis. Lancet Infect Dis. 2005;5(9):594.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33(7):947–53.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Ochs L, Shu XO, Miller J, Enright H, Wagner J, Filipovich A. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86(10):3979–86.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Roy V, Weisdorf D. Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review. Bone Marrow Transplant. 1997;19(5):467–70.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7(1):11–7.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, et al. Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant. 2005;35(5):497–9.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47–53.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96(1):e1–3. author reply e4PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40(3):271–8.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res. 2009;42(3):289–93.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Arango JI, Restrepo A, Schneider DL, Callander NS, Ochoa-Bayona JL, Restrepo MI, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006;37(5):517–21.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Bobak D, Arfons LM, Creger RJ, Lazarus HM. Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm? Bone Marrow Transplant. 2008;42(11):705–13.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Alonso CD, Treadway SB, Hanna DB, Huff CA, Neofytos D, Carroll KC, Marr KA. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012;54(8):1053–63.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109–13.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–9.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Biller P, Shank B, Lind L, Brennan M, Tkatch L, Killgore G, et al. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol. 2007;28(2):198–201.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Goorhuis A, Van der Kooi T, Vaessen N, Dekker FW, Van den Berg R, Harmanus C, et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis. 2007;45(6):695–703.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and MarrowTransplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12 Pt 1):979–95.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41(10):1372–82.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996;23(4):795–805.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis. 2011;24(6):545–53.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Chang J, Powles R, Mehta J, Paton N, Treleaven J, Jameson B. Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment. Clin Infect Dis. 1995;21(5):1289–90.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Harrington RD, Woolfrey AE, Bowden R, McDowell MG, Hackman RC. Legionellosis in a bone marrow transplant center. Bone Marrow Transplant. 1996;18(2):361–8.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol. 1996;52(2):82–9.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Kalhs P, Panzer S, Kletter K, Minar E, Stain-Kos M, Walter R, et al. Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease. Ann Intern Med. 1988;109(6):461–4.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Youssef S, Rodriguez G, Rolston KV, Champlin RE, Raad II, Safdar A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989–2005. Medicine (Baltimore). 2007;86(2):69–77.CrossRefGoogle Scholar
  61. 61.
    Engelhard D, Cordonnier C, Shaw PJ, Parkalli T, Guenther C, Martino R, Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT), et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol. 2002;117(2):444–50.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Cordonnier C, Martino R, Trabasso P, Held TK, Akan H, Ward MS, European Blood and Marrow Transplant Group Infectious Diseases Working Party, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38(9):1229–36.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Unal E, Yen C, Saiman L, George D, Della-Latta P, van de Ven C, et al. A low incidence of nontuberculous mycobacterial infections in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2006;12(11):1188–97.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis. 2004;38(10):1428–39.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Au WY, Cheng VC, Ho PL, Yuen KY, Hung I, Ma SY, et al. Nontuberculous mycobacterial infections in Chinese hematopoietic stem cell transplantation recipients. Bone Marrow Transplant. 2003;32(7):709–14.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant. 2000;6(4):361–9.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Russo RL, Dulley FL, Suganuma L, França IL, Yasuda MA, Costa SF. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis. 2010;14(Suppl 3):e187–91.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Navari RM, Sullivan KM, Springmeyer SC, Siegel MS, Meyers JD, Buckner CD, et al. Mycobacterial infections in marrow transplant patients. Transplantation. 1983;36(5):509–13.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Kurzrock R, Zander A, Vellekoop L, Kanojia M, Luna M, Dicke K. Mycobacterial pulmonary infections after allogeneic bone marrow transplantation. Am J Med. 1984;77(1):35–40.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Wang JY, Chang YL, Lee LN, Chen JH, Tang JL, Yang PC, Lee YC. Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Ann Thorac Surg. 2004;78(1):267–72.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Daly AS, McGeer A, Lipton JH. Systemic nocardiosis following allogeneic bone marrow transplantation. Transpl Infect Dis. 2003;5(1):16–20.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Pao M, Papadopoulos EB, Chou J, Glenn H, Castro-Malaspina H, Jakubowski AA, et al. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2008;14(9):1022–30.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Toscano CM, Bell M, Zukerman C, Shelton W, Novicki TJ, Nichols WG, et al. Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care. Am J Infect Control. 2009;37(4):327–34.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Benjamin D, Miller WC, Bayliff S, Martel L, Alexander K, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J. 2002;21(3):227–34.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50(11):1439–47.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Urwijitaroon Y, Teawpatanataworn S, Kitjareontarm A. Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors. Southeast Asian J Trop Med Public Health. 1993;24(Suppl 1):180–2.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in southern, Brazil. Rev Soc Bras Med Trop. 2010;43(4):359–61.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Miller W, Flynn P, McCullough J, Balfour HH Jr, Goldman A, Haake R, et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood. 1986;67(4):1162–7.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Montesinos P, Sanz J, Cantero S, Lorenzo I, Martín G, Saavedra S, et al. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2009;15(6):730–40.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 1993;118(3):173–8.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med. 1993;118(3):179–84.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Ayala E, Greene J, Sandin R, Perkins J, Field T, Tate C, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37(9):851–6.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Boeckh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407–14.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185(3):273–82.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–58.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–9.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Alexander BT, Hladnik LM, Augustin KM, Casabar E, McKinnon PS, Reichley RM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy. 2010;30(6):554–61.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Mui TS, Kapp M, Einsele H, Grigoleit GU. T-cell therapy for cytomegalovirus infection. Curr Opin Organ Transplant. 2010;15(6):744–50.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Bernstein DI. Vaccines for cytomegalovirus. Infect Disord Drug Targets. 2011;11(5):514–25.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Kharfan-Dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2012;12(4):290–9.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Jagadeesh D, Woda BA, Draper J, Evens AM. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations. Curr Treat Options in Oncol. 2012;13(1):122–36.CrossRefGoogle Scholar
  92. 92.
    Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009;113(20):4992–5001.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008;42(3):181–6.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(2):287–91.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11(5):383–92.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964–73.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 1980;142(3):338–46.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis. 1984;149(5):750–6.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Gasparetto EL, Escuissato DL, Inoue C, Marchiori E, Müller NL. Herpes simplex virus type 2 pneumonia after bone marrow transplantation: high-resolution CT findings in 3 patients. J Thorac Imaging. 2005;20(2):71–3.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Ramsey PG, Fife KH, Hackman RC, Meyers JD, Corey L. Herpes simplex virus pneumonia: clinical, virologic, and pathologic features in 20 patients. Ann Intern Med. 1982;97(6):813–20.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Kaufman B, Gandhi SA, Louie E, Rizzi R, Illei P. Herpes simplex virus hepatitis: case report and review. Clin Infect Dis. 1997;24(3):334–8.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Momméja-Marin H, Lafaurie M, Scieux C, Galicier L, Oksenhendler E, Molina JM. Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adults. Clin Infect Dis. 2003;37(11):1527–33.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Robinson MJ, Newton C. Bilateral herpes simplex keratitis in a patient with graft-vs-host disease. Am J Ophthalmol. 1991;112(4):468–9.CrossRefGoogle Scholar
  104. 104.
    Ballen KK, Donadio D, Bouloux C, McCarthy P, Weinstein H, Antin JH. Herpes simplex virus and neutropenia following bone marrow transplantation. Transplantation. 1992;54(3):553–5.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Rogers JE, Cumpston A, Newton M, Craig M. Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population. Transpl Infect Dis. 2011;13(5):480–4.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Oshima K, Takahashi T, Mori T, Matsuyama T, Usuki K, Asano-Mori Y, et al. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis. 2010;12(5):421–7.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Steer CB, Szer J, Sasadeusz J, Matthews JP, Beresford JA, Grigg A. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant. 2000;25(6):657–64.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Kim DH, Messner H, Minden M, Gupta V, Kuruvilla J, Wright J, Lipton J. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis. 2008;10(2):90–8.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Zerr DM, Boeckh M, Delaney C, Martin PJ, Xie H, Adler AL, et al. HHV-6 reactivation and associated sequelae after hematopoietic cell transplant. Biol Blood Marrow Transplant. 2012;18(11):1700–8.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis. 2005;40(7):932–40.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007;39(7):425–9.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Hill JA, Koo S, Guzman Suarez BB, Ho VT, Cutler C, Koreth J, et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012;18(11):1638–48.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Yamane A, Mori T, Suzuki S, Mihara A, Yamazaki R, Aisa Y, et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant. 2007;13(1):100–6.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Olli-Lähdesmäki T, Haataja L, Parkkola R, Waris M, Bleyzac N, Ruuskanen O. High-dose ganciclovir in HHV-6 encephalitis of an immunocompetent child. Pediatr Neurol. 2010;43(1):53–6.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Yoshikawa T, Yoshida J, Hamaguchi M, Kubota T, Akimoto S, Ihira M, et al. Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation. J Med Virol. 2003;70(3):440–3.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    de Medeiros BC, Rezuke WN, Ricci A Jr, Tsongalis G, Shen PU, Bona RD, et al. Kaposi’s sarcoma following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. Acta Haematol. 2000;104(2–3):115–8.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    van Tol MJD, Kroes ACM, Schinkel J, Dinkelaar W, Claas ECJ, et al. Adenovirus infection in paediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36(1):39–50.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Taniguchi K, Yoshihara S, Tamaki H, Fujimoto T, Ikegame K, Kaida K, et al. Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. Ann Hematol. 2012;91(8):1305–12.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis. 2004;39(9):1300–6.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98(3):573–8.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation. 2009;88(10):1222–6.PubMedCrossRefPubMedCentralGoogle Scholar
  122. 122.
    Debur MC, Vidal LR, Stroparo E, Nogueira MB, Almeida SM, Takahashi GA, et al. Human metapneumovirus infection in hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2010;12(2):173–9.PubMedCrossRefPubMedCentralGoogle Scholar
  123. 123.
    Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood. 2010;115(10):2088–94.PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med. 2011;32(4):471–93.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85(5):278–87.CrossRefGoogle Scholar
  126. 126.
    Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(9):1049–59.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16(6):809–17.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011;56(3):495–7.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Lekakis LJ, Macrinici V, Baraboutis IG, Mitchell B, Howard DS. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. Am J Hematol. 2009;84(4):243–6.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    O’Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, et al. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant. 2009;15(9):1038–1048 e1.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant. 2008;41(1):11–8.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Steurer M, Clausen J, Gotwald T, Gunsilius E, Stockhammer G, Gastl G, Nachbaur D. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation. 2003;76(2):435–6.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Goodrich JM, Reed EC, Mori M, Fisher LD, Skerrett S, Dandliker PS, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis. 1991;164(4):731–40.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181(1):309–16.PubMedCrossRefPubMedCentralGoogle Scholar
  135. 135.
    Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–51.CrossRefGoogle Scholar
  136. 136.
    Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.CrossRefGoogle Scholar
  137. 137.
    Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96(6):2055–61.Google Scholar
  138. 138.
    Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–73.PubMedCrossRefPubMedCentralGoogle Scholar
  139. 139.
    Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;48(12):1695–703.PubMedCrossRefPubMedCentralGoogle Scholar
  140. 140.
    Rossetti F, Brawner DL, Bowden R, Meyer WG, Schoch HG, Fisher L, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis. 1995;20(4):801–11.PubMedCrossRefPubMedCentralGoogle Scholar
  141. 141.
    Hart PD, Russell E Jr, Remington JS. The compromised host and infection. II. Deep fungal infection. J Infect Dis. 1969;120(2):169–91.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Held J, Kohlberger I, Rappold E, Busse Grawitz A, Häcker G. Comparison of (1->3)-beta-D-glucan, mannan/anti-mannan antibodies, and Cand-Tec Candida antigen as serum biomarkers for candidemia. J Clin Microbiol. 2013;51(4):1158–64.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Caspofungin Invasive Candidiasis Study Group, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–9.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Micafungin Invasive Candidiasis Working Group, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–27.CrossRefGoogle Scholar
  145. 145.
    Lockhart SR, Wagner D, Iqbal N, Pappas PG, Andes DR, Kauffman CA, et al. Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006. J Clin Microbiol. 2011;49(7):2404–10.PubMedPubMedCentralCrossRefGoogle Scholar
  146. 146.
    Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Infectious Diseases Society of America, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175(6):1459–66.PubMedPubMedCentralCrossRefGoogle Scholar
  148. 148.
    Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–66.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Seo KW, Kim DH, Sohn SK, Lee NY, Chang HH, Kim SW, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36(12):1089–95.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47(8):1041–50.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359(17):1766–77.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, VAN DEN Brink M, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci. 2005;1062:95–103.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, Giles SS, et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet. 2008;4(6):e1000101.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Mezger M, Steffens M, Beyer M, Manger C, Eberle J, et al. Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood. 2008;111(2):534–6.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    Sainz J, Pérez E, Gómez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. J Clin Immunol. 2008;28(5):473–85.PubMedCrossRefPubMedCentralGoogle Scholar
  156. 156.
    Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M, alloPBSCT and Infectious/nonifectious Complications Subcommittees of the Grupo Español de Transplante Hematopoyético (GETH), et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;28(4):341–7.PubMedCrossRefPubMedCentralGoogle Scholar
  157. 157.
    Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102(3):827–33.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Labbé AC, Su SH, Laverdière M, Pépin J, Patiño C, Cohen S, et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2007;13(10):1192–200.PubMedCrossRefGoogle Scholar
  159. 159.
    Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34(7):909–17.CrossRefGoogle Scholar
  160. 160.
    Kojima R, Tateishi U, Kami M, Murashige N, Nannya Y, Kusumi E, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11(7):506–11.PubMedCrossRefPubMedCentralGoogle Scholar
  161. 161.
    Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190(3):641–9.PubMedCrossRefGoogle Scholar
  162. 162.
    Boutboul F, Alberti C, Leblanc T, Sulahian A, Gluckman E, Derouin F, Ribaud P. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis. 2002;34(7):939–43.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Nguyen MH, Leather H, Clancy CJ, Cline C, Jantz MA, Kulkarni V, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant. 2011;17(7):1043–50.PubMedCrossRefGoogle Scholar
  164. 164.
    Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762–9.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother. 2005;49(9):3984–5.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Hage CA, Reynolds JM, Durkin M, Wheat J, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol. 2007;45(2):676–7.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Infectious Diseases Society of America, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–9.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group, Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010;95(10):1762–8.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    El-Cheikh J, Castagna L, Wang L, Esterni B, Faucher C, Fürst S, et al. Impact of prior invasive aspergillosis on outcome in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2010;51(9):1705–10.PubMedCrossRefPubMedCentralGoogle Scholar
  173. 173.
    Gaziev D, Baronciani D, Galimberti M, Polchi P, Angelucci E, Giardini C, et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant. 1996;17(3):409–14.PubMedPubMedCentralGoogle Scholar
  174. 174.
    Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis. 2004;39(5):743–6.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2004;38(9):1237–42.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Müller FM, et al. Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis. 2001;33(11):1871–8.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90(3):999–1008.PubMedPubMedCentralGoogle Scholar
  179. 179.
    Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40(1):89–99.PubMedCrossRefPubMedCentralGoogle Scholar
  180. 180.
    Bhatti Z, Shaukat A, Almyroudis NG, Segal BH. Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients. Mycopathologia. 2006;162(1):1–15.PubMedCrossRefPubMedCentralGoogle Scholar
  181. 181.
    De Castro N, Neuville S, Sarfati C, Ribaud P, Derouin F, Gluckman E, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant. 2005;36(10):879–83.PubMedCrossRefPubMedCentralGoogle Scholar
  182. 182.
    Torres HA, Chemaly RF, Storey R, Aguilera EA, Nogueras GM, Safdar A, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis. 2006;25(6):382–8.PubMedCrossRefPubMedCentralGoogle Scholar
  183. 183.
    Lyytikäinen O, Ruutu T, Volin L, Lautenschlager I, Jokipii L, et al. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;17(6):1057–9.PubMedPubMedCentralGoogle Scholar
  184. 184.
    Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant. 1992;10(3):267–72.PubMedPubMedCentralGoogle Scholar
  185. 185.
    Mulanovich VE, Ahmed SI, Öztürk T, Khokhar FA, Kontoyiannis DP, de Lima M. Toxoplasmosis in allo-SCT patients: risk factors and outcomes at a transplantation center with a low incidence. Bone Marrow Transplant. 2011;46(2):273–7.PubMedCrossRefPubMedCentralGoogle Scholar
  186. 186.
    Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant. 1994;13(5):549–57.PubMedPubMedCentralGoogle Scholar
  187. 187.
    Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJ, Lariviere M. Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis. 1992;15(2):267–70.PubMedCrossRefPubMedCentralGoogle Scholar
  188. 188.
    Cavattoni I, Ayuk F, Zander AR, Zabelina T, Bacher A, Cayroglu E, et al. Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. Leuk Lymphoma. 2010;51(8):1530–5.PubMedCrossRefPubMedCentralGoogle Scholar
  189. 189.
    Edvinsson B, Lundquist J, Ljungman P, Ringdén O, Evengård B. A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation. APMIS. 2008;116(5):345–51.PubMedCrossRefPubMedCentralGoogle Scholar
  190. 190.
    Bautista G, Ramos A, Forés R, Regidor C, Ruiz E, de Laiglesia A, et al. Toxoplasmosis in cord blood transplantation recipients. Transpl Infect Dis. 2012;14(5):496–501.PubMedCrossRefPubMedCentralGoogle Scholar
  191. 191.
    Derouin F, Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14(12):1089–101.PubMedCrossRefPubMedCentralGoogle Scholar
  192. 192.
    Wirk B, Wingard JR. Strongyloides stercoralis hyperinfection in hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):143–8.PubMedCrossRefPubMedCentralGoogle Scholar
  193. 193.
    Gupta S, Jain A, Fanning TV, Couriel DR, Jimenez CA, Eapen GA. An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer. 2006;6:87.PubMedPubMedCentralCrossRefGoogle Scholar
  194. 194.
    Recommendations of the Center for International Blood and Marrow Transplant Research (CIBMTR®), the National Marrow Donor Program (NMDP), the European Blood and Marrow Transplant Group (EBMT), the American Society of Blood and Marrow Transplantation (ASBMT), the Canadian Blood and Marrow Transplant Group (CBMTG), the Infectious Disease Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the Association of Medical Microbiology and Infectious Diseases Canada (AMMI), the Centers for Disease Control and Prevention (CDC), Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Bone Marrow Transplant. 2009;44(8):453–558.CrossRefGoogle Scholar
  195. 195.
    Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Disease Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Diseases Canada, Centers for Disease Control and Prevention, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Marcus R. Pereira
    • 1
    Email author
  • Stephanie M. Pouch
    • 2
  • Brian Scully
    • 1
  1. 1.Department of Medicine – Infectious DiseasesColumbia University Medical CenterNew YorkUSA
  2. 2.Division of Infectious DiseasesEmory UniversityAtlantaUSA

Personalised recommendations